Jonas Salk vaccine. A few weeks later, Salk injected children at the Polk State School for the retarded and feeble-minded. In 1954 he tested the vaccine on about one million children, known as the polio pioneers. The vaccine was announced as safe on April 12, 1955. The project became large, involving 100 million contributors to the March of Dimes, and 7 million volunteers. The foundation allowed itself to go into debt to finance the final research required to develop the Salk vaccine. Salk worked incessantly for two and a half years. Salk's inactivated polio vaccine was the first vaccine for the disease;
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood